Skip to Content
Merck
CN
All Photos(1)

Key Documents

Safety Information

Y4877

Sigma-Aldrich

YM 976

≥98% (HPLC)

Synonym(s):

4-(3-Chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C17H16N3OCl
CAS Number:
Molecular Weight:
313.78
MDL number:
UNSPSC Code:
41106305
PubChem Substance ID:
NACRES:
NA.77

Assay

≥98% (HPLC)

form

solid

color

yellow

mp

132.7-134.0 °C (lit.)

solubility

DMSO: ≥10 mg/mL

storage temp.

2-8°C

SMILES string

CCN1C(=O)N=C(c2cccc(Cl)c2)c3ccc(CC)nc13

InChI

1S/C17H16ClN3O/c1-3-13-8-9-14-15(11-6-5-7-12(18)10-11)20-17(22)21(4-2)16(14)19-13/h5-10H,3-4H2,1-2H3

InChI key

MNHXYNNKDDXKNP-UHFFFAOYSA-N

Biochem/physiol Actions

Phosphodiesterase type IV (PDE4) inhibitor. Anti-inflammatory activity without emesis. Related to asthma.
Phosphodiesterase type IV (PDE4) inhibitor. Exhibits anti-inflammatory activity without emesis. PDE4 inhibitors are of interest for asthma.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Massimo Nabissi et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 105, 1248-1253 (2018-07-20)
Chronic obstructive pulmonary disease (COPD) is a respiratory disorder characterized by a progressive and irreversible airflow limitation. COPD is associated to a chronic inflammatory response with infiltration of inflammatory cells in the surface epithelium of large airways and abnormalities in
Will McDonough et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 34(9), 12533-12548 (2020-08-02)
Inhibitors of cAMP-phosphodiesterase 4 (PDE4) exert a number of promising therapeutic benefits, but adverse effects, in particular emesis and nausea, have curbed their clinical utility. Here, we show that PAN-selective inhibition of PDE4, but not inhibition of PDE3, causes a

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service